PARP1 and neoplasm: In addition, our findings raise the possibility that enhancing anti-tumor macrophage function with either MNA or olaparib can potentially increase the therapeutic activity of targeted, non-myelosuppressive agents including antibodies or low-dose chemotherapy, all of which are currently being studied in combination with PARP inhibition (Kim et al., 2021).